What Is CJC-1295?

1. How does CJC-1295 work?

GHRH is a signal that tells the pituitary to produce and release growth hormone, abbreviated GH. CJC-1295 mimics that signal. GH then acts on tissues and stimulates production of insulin-like growth factor 1, or IGF-1.

Researchers developed the long-acting molecule to keep a GHRH signal active for longer. In Jetté and colleagues’ 2005 experiments, modified GHRH peptides bound to albumin retained biological activity. Albumin is abundant in blood and lasts much longer than an unprotected short peptide. Attaching the signal to it prolongs exposure.

This mechanism differs from injecting recombinant HGH, which supplies growth hormone directly. CJC-1295 relies on the pituitary’s ability to respond. It also differs from GLP-1 medications: sharing the word peptide does not imply the same appetite or weight effects.

A higher IGF-1 result indicates a response somewhere along this hormone pathway. It does not measure the size of a muscle, the strength of a tendon or the quality of a night’s sleep.

2. CJC-1295 DAC vs no DAC

DAC changes the molecule’s behavior. It is an albumin-binding modification, rather than a preservative or an extra ingredient mixed into the vial. The FDA’s chemical review distinguishes CJC-1295 substances with and without this modification.

The name on a sales page cannot establish that a product matches the material used in a trial. A source that cites an eight-day half-life while describing daily “no DAC” injections has mixed evidence from different forms.

The frequently repeated 30-minute no-DAC half-life also needs a source specifying the molecule, species and route. The human DAC studies below cannot validate that number or turn it into an injection schedule.

3. What do the human CJC-1295 studies show?

The published studies answer questions about hormone exposure and biological activity. Their endpoints are narrower than the physique claims often attached to them.

The 2009 analysis used a subset of participants from the pulsatility study, according to the FDA review. It should not be counted as an independent group of 11 additional users.

A fold increase describes a ratio to baseline. An IGF-1 result at three times baseline does not mean three times the muscle growth. Nor does the upper end of a dose-ranging study describe what every participant experienced.

4. Does DAC cause a constant “GH bleed”?

“GH bleed” is informal language used in peptide discussions for elevated GH between pulses. The Ionescu and Frohman study provides a more precise description: pulse frequency and magnitude were unchanged, while the trough, or between-pulse level, rose. Mean GH increased 46% and IGF-1 increased 45% at the sampled follow-up.

The researchers collected blood every 20 minutes for 12 hours overnight. That let them distinguish pulses from the underlying level. A single random GH blood test cannot reconstruct that pattern.

So preserved pulsatility and sustained stimulation can occur together. Calling the response “natural” leaves out the higher background exposure. Conversely, saying DAC eliminated GH pulses contradicts what this experiment found. The study did not determine whether the altered pattern improves long-term health or performance.

5. CJC-1295 benefits for muscle, fat loss, sleep and recovery

For someone lifting four days a week, the useful result would be a change in muscle size, strength or repeat-session performance. For someone cutting, it might be fat lost while strength holds steady. The studies above supply no dependable estimate for either goal.

These are unanswered questions, rather than evidence that every proposed benefit is impossible. They do mean a promised number of pounds gained, percentage of fat lost or weeks to a transformation lacks support from these trials.

Before-and-after photos become especially difficult to interpret when the person also changes calories, training, testosterone or other peptides. Even a DEXA lean-mass increase includes non-fat tissues and water; it does not isolate new contractile muscle. A sleep wearable’s deep-sleep estimate also cannot substitute for a controlled sleep study.

The same evidence gap applies to adding CJC-1295 during GLP-1 weight loss. Demonstrating muscle preservation would require studying that combination during a calorie deficit, with muscle and functional outcomes.

6. CJC-1295 and ipamorelin

Ipamorelin acts through the ghrelin receptor pathway, while CJC-1295 acts through the GHRH receptor. Raun and colleagues characterized ipamorelin’s GH-releasing activity in animal experiments. Two routes to GH release give researchers a rationale to investigate a combination.

They do not establish that a commercial blend improves recovery, or that a particular milligram ratio is effective. The CJC-1295 studies in the table did not test an ipamorelin stack.

Ipamorelin has also been studied in humans, but for a different question. A randomized trial after bowel surgery investigated recovery of gastrointestinal function. Its primary endpoint did not show a statistically significant advantage over placebo. That trial cannot validate a bodybuilding combination or its subcutaneous dosing schedule.

If a testimonial includes both peptides, it cannot separate their contributions. Adding several agents at once also makes a new symptom harder to attribute. A prefilled blend does not resolve either problem.

7. Half-life, dosage and time to results

Teichman and colleagues estimated a half-life of 5.8–8.1 days for long-acting CJC-1295. Repeated administration produced cumulative effects; mean IGF-1 remained above baseline for up to 28 days after multiple doses.

Half-life describes the time for concentration to fall by half. It is separate from the duration of a hormone response, the time to a physical result and the time an adverse effect may last. A half-life visualization can illustrate declining exposure, but cannot predict an individual’s IGF-1 response.

The early trials tested single and repeated subcutaneous doses to study exposure and tolerability. They did not establish an optimal bodybuilding dose, bedtime schedule, fasting window or eight-week cycle. Converting experimental doses into a personal protocol would add a recommendation the studies did not validate.

Long exposure also means skipping tomorrow’s injection does not immediately remove the preceding dose. A short break should not be assumed to reset the hormonal system. For no-DAC products, the DAC half-life offers no basis for estimating that interval.

8. CJC-1295 side effects and unresolved risks

The early Teichman trials reported no serious adverse reactions. That finding covers a short observation period and a selected population; it cannot settle safety after months or years.

In its 2024 clinical review, FDA describes injection reactions, headache, gastrointestinal symptoms, flushing, transient low blood pressure and increased heart rate. The agency’s current safety page identifies increased heart rate and systemic vasodilatory reactions among serious events associated with CJC-1295. Vasodilation means widening of blood vessels, which can cause warmth, flushing and a drop in blood pressure.

There are also risks inferred from stimulating the GH/IGF-1 pathway. Tesamorelin’s approved label, for another GHRH analogue, addresses glucose intolerance, fluid retention and malignancy-related precautions. Those warnings explain why the pathway warrants medical assessment. Their event rates cannot be assigned to CJC-1295.

CJC-1295’s long-term cancer risk remains unquantified. Growth signaling offers a biological reason for concern, but neither a cancer claim nor a safety guarantee follows from the mechanism alone.

FDA also flags potential immune reactions and peptide-impurity issues. A purity percentage cannot by itself establish sterility, correct dose or the safety of repeated injections. Chest pain, fainting or breathing difficulty after an injection warrants urgent medical attention.

9. CJC-1295 vs sermorelin, tesamorelin and HGH

The Egrifta WR label excludes general weight-loss management from tesamorelin’s indication. Even an approved drug in this family needs its results tied to the population and outcome studied.

10. FDA status, tested sport and useful records

CJC-1295 has no FDA-approved use. As checked on September 21, 2026, FDA’s safety page places it under bulk substances whose nominations were withdrawn and retains the safety concerns. A change in a compounding nomination’s status does not establish drug approval. Compounded drugs themselves are not FDA-approved.

For tested athletes, WADA’s 2026 Prohibited List names CJC-1295 in section S2.2.4. It is prohibited at all times, including outside competition.

A useful record for a clinician separates the intended outcome from the hormone result. Log the exact product and DAC status, other medications, symptoms, laboratory dates, training changes and the method used for body-composition measurements. Keep waist, weight, strength and sleep observations as separate measurements in a tracking record.

If IGF-1 rises but strength and waist remain unchanged, record all three results. If swelling or a racing heart appears, record that too and seek medical assessment. A log that captures only the hoped-for benefit gives an incomplete account of the exposure.

11. CJC-1295 FAQ

• What is CJC-1295 used for?

  Researchers have studied CJC-1295 as a way to stimulate growth hormone release. Clinics and sellers promote it for body composition, recovery and sleep, but those benefits have not been established in controlled human outcome trials.

• What is the difference between CJC-1295 DAC and no DAC?

  DAC is an albumin-binding modification that prolongs exposure. Products sold as no DAC, often called modified GRF(1–29), lack that modification. The two should not share an assumed half-life or evidence base.

• What is CJC-1295's half-life?

  Teichman and colleagues estimated 5.8–8.1 days for the long-acting form. That figure does not apply to no-DAC products.

• Does CJC-1295 build muscle or burn fat?

  The human hormone studies do not provide an expected muscle gain or fat-loss percentage. A rise in IGF-1 cannot establish how much muscle someone gains or whether their waist shrinks.

• Does CJC-1295 improve deep sleep?

  A sleep benefit has not been established. Overnight blood sampling measures hormone secretion; it does not measure deep sleep or demonstrate improvement in insomnia.

• Does CJC-1295 work better with ipamorelin?

  The compounds stimulate GH through different receptors, but the clinical studies cited here do not test the combination for physique or recovery benefits. They cannot establish an effective blend ratio or long-term safety.

• What is the best CJC-1295 dosage or cycle?

  There is no validated enhancement dose or cycle. Early dose-finding experiments do not establish a bodybuilding schedule, and a protocol for one form cannot be assumed to apply to another.

• Is CJC-1295 safer than HGH?

  Stimulating your own GH does not establish superior safety. Adequate long-term comparisons in healthy users are lacking, and prolonged GH/IGF-1 stimulation still raises metabolic and other safety questions.

• Does CJC-1295 cause cancer?

  Human data cannot quantify its long-term cancer risk. GH and IGF-1 affect growth signaling, but that mechanism alone cannot prove that CJC-1295 causes cancer or establish that it is safe in someone with a cancer history.

• Is CJC-1295 FDA-approved or allowed in tested sport?

  CJC-1295 has no FDA-approved use. WADA's 2026 Prohibited List names it among growth hormone-releasing factors, prohibited both in and out of competition.

12. Sources